Software Biomax Informatics krijgt licentie van mondiaal farmaceutisch bedrijf Boehringer Ingelheim om kennisplatform op te bouwen voor doelgerichte ontdekking
PLANEGG, Germany–(BUSINESS WIRE)– Biomax Informatics AG kondigt aan dat vaste klant Boehringer Ingelheim een meerjarige licentie voor de BioXM™ Knowledge Management Environment heeft getekend ter ondersteuning van wereldwijd onderzoek. Daarnaast heeft het bedrijf zijn licentie voor het BioRS™ Integratie- en Opvraagsysteem van Biomax verlengd.
Boehringer Ingelheim maakt gebruik van de BioXM™ Knowledge Management Environment om een kennisplatform op te bouwen en te onderhouden dat het onderzoek van het bedrijf op wereldwijde schaal ondersteunt. Het BioXM platform maakt gebruik van de bestaande BioRS infrastructuur van Boehringer Ingelheim om informatie uit eigen systemen en andere propriëtaire en publieke databronnen semantisch te integreren, inclusief pathways, compounds, sequences, genotypes, fenotypes, experimentele data en tekst mining resultaten. Met BioXM-platform hebben alle externe toepassingen van het bedrijf rechtstreeks of via API’s (Application Programming Interfaces) toegang tot gegevens en worden alle geïntegreerde databanken regelmatig bijgewerkt.
Biomax Informatics software licensed by global pharma company, Boehringer Ingelheim, to build a target discovery knowledge platform
PLANEGG, Germany–(BUSINESS WIRE)– Biomax Informatics AG announces that their longtime client, Boehringer Ingelheim, has signed a multi-year license for the BioXM™ Knowledge Management Environment to support their global target discovery research. In addition, the company has extended their license for Biomax’s BioRS™ Integration and Retrieval System.
Boehringer Ingelheim is using the BioXM™ Knowledge Management Environment to build and maintain a target discovery knowledge platform that supports the company’s research on a global scale. The BioXM platform leverages Boehringer Ingelheim’s existing BioRS infrastructure to semantically integrate information from the company’s in-house systems and other proprietary and public data sources including pathways, compounds, sequences, genotypes, phenotypes, experimental data and text mining results. The BioXM platform allows all of the company’s external applications to access the data either directly or through application programming interfaces (APIs) and automates the updating of all integrated databases on a regular schedule.
“Boehringer Ingelheim has used the BioRS software for data integration for many years. Adding the BioXM software now lets them model their complete target discovery process in one easy-to-use, sustainable knowledge hub,” explained Dr. Kaj Albermann, who manages the Boehringer Ingelheim project at Biomax.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 143 affiliates and a total of around 50,000 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine. www.boehringer-ingelheim.com
About Biomax
Biomax Informatics provides computational solutions for better decision making and knowledge management in the life sciences. They help customers generate value by integrating information from proprietary and public resources to enable a knowledge-based approach to developing innovative life science products. Biomax’s worldwide customer community includes clinics, companies and research organizations that are successful in drug discovery, diagnostics, fine chemicals, food and plant production. www.biomax.com
Biomax, BioRS and BioXM are registered trademarks of Biomax Informatics AG in Germany and other countries. Registered names, trademarks, etc., used in this document, even when not specifically marked as such, are not to be considered unprotected by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180508005093/en/
Contacts
Biomax Informatics AG
Dr. Philipp Krubasik, +49 89 895574-0
philipp.krubasik@biomax.com
Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is. Check out our twitter: @NewsNovumpr